FDA approves Lundbeck's Onfi for rare, severe epileptic seizures

Lundbeck and its US manufacturing partner Catalent Pharma won US FDA approval of Onfi (clobazam) as an adjunctive treatment for seizures in patients two years and up with Lennox-Gastaut syndrome, a rare but severe form of epilepsy.

Lundbeck and its US manufacturing partner Catalent Pharma won US FDA approval of Onfi (clobazam) as an adjunctive treatment for seizures in patients two years and up with Lennox-Gastaut syndrome, a rare but severe form of epilepsy.

Patients with Lennox-Gastaut, which typically is diagnosed in childhood – often persisting into adulthood – generally experience multiple types of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Alimentary/Metabolic

More from Therapeutic Category